Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

RICHARD M GLOVER

Allopathic & Osteopathic Physicians Family Medicine

NPI
1063480937
CMS profile
48347
Location
NEWTON, KS

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$1,870.35

159 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $1,870.35 159

By paying entity

PY2022 · entire year · sorted by reported total

Page 4 of 4; records 151–159 of 159 matching records. This page contains 9 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

RICHARD M GLOVER

NPI 1063480937 · CMS profile ID 48347

Allopathic & Osteopathic Physicians / Family Medicine

NEWTON, KS

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 4 of 4; records 151–159 of 159 matching records. This page contains 9 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1063480937?year=2022&recipient=provider&page=4#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
RICHARD M GLOVER, NPI 1063480937, CMS profile ID 48347. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 4; records 151–159 of 159 matching records. This page contains 9 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1063480937?year=2022&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). RICHARD M GLOVER, NPI 1063480937, CMS profile ID 48347. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 4; records 151–159 of 159 matching records. This page contains 9 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1063480937?year=2022&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
RICHARD M GLOVER, NPI 1063480937, CMS profile ID 48347, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 4 of 4; records 151–159 of 159 matching records. This page contains 9 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1063480937?year=2022&recipient=provider&page=4#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

159 matching records · $1,870.35 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 159 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 151–159 of 159.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Bayer HealthCare Pharmaceuticals Inc. $6.3001/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929907541 CMS
ABBVIE INC. $13.5701/19/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891043087 CMS
Abbott Laboratories $13.0801/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 920403705 CMS
Novo Nordisk Inc $9.6701/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 899561109 CMS
Teva Pharmaceuticals USA, Inc. $13.3001/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 954639317 CMS
UPSHER-SMITH LABORATORIES LLC $23.9001/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 912294311 CMS
Amgen Inc. $16.9701/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939372313 CMS
Amgen Inc. $6.0201/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939372305 CMS
Daiichi Sankyo Inc. $15.6001/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 930799769 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $3,339.29 114
PY2020 $1,386.56 110
PY2021 $1,859.36 142
PY2022 $1,870.35 159
PY2023 $1,708.56 130
PY2024 $2,143.53 125
PY2025 $1,783.44 110

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $783,129.09 107
PY2024 Recipient $12,977.61 1
PY2024 Principal investigator $1,043,028.66 73
PY2023 Recipient $620.01 1
PY2023 Principal investigator $2,541,504.79 689
PY2022 Recipient $35,758.66 6
PY2022 Principal investigator $6,784,890.70 1,814
PY2021 Principal investigator $6,776,236.49 415
PY2020 Recipient $236.50 1
PY2020 Principal investigator $965,254.86 71
PY2019 Recipient $705.39 1
PY2019 Principal investigator $728,930.78 104

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

107 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $600.00 12/31/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Ubrogepant for the Preventive Treatment of Menstrual Migraine with an Open-Label Extension No dispute reported 06/30/2026 1202533461
Principal investigator 1 ABBVIE INC. $2,107.00 12/30/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202532190
Principal investigator 1 PFIZER INC. $23,950.00 12/27/2025 Non-covered Recipient Entity
Alliance for Multispecialty Research LLC
A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIOIDES DIFFICILE VACCINE IN ADULTS 65 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228751181
Principal investigator 1 PFIZER INC. $426.60 12/23/2025 Non-covered Recipient Entity
AMR Clinical
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1228725054
Principal investigator 1 PFIZER INC. $426.60 12/23/2025 Non-covered Recipient Entity
AMR Clinical
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1228725056
Principal investigator 1 PFIZER INC. $426.60 12/23/2025 Non-covered Recipient Entity
AMR Clinical
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1228725174
Principal investigator 1 PFIZER INC. $426.60 12/23/2025 Non-covered Recipient Entity
AMR Clinical
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1228725176
Principal investigator 1 PFIZER INC. $426.60 12/23/2025 Non-covered Recipient Entity
AMR Clinical
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1228725486
Principal investigator 1 PFIZER INC. $426.60 12/23/2025 Non-covered Recipient Entity
AMR Clinical
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1228726098
Principal investigator 1 PFIZER INC. $426.60 12/23/2025 Non-covered Recipient Entity
AMR Clinical
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1228726358
Principal investigator 1 PFIZER INC. $426.60 12/23/2025 Non-covered Recipient Entity
AMR Clinical
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1228731280
Principal investigator 1 PFIZER INC. $426.60 12/23/2025 Non-covered Recipient Entity
AMR Clinical
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1228731379
Principal investigator 1 PFIZER INC. $426.60 12/23/2025 Non-covered Recipient Entity
AMR Clinical
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1228731569
Principal investigator 1 PFIZER INC. $426.60 12/23/2025 Non-covered Recipient Entity
AMR Clinical
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1228733247
Principal investigator 1 PFIZER INC. $426.60 12/23/2025 Non-covered Recipient Entity
AMR Clinical
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1228734899
Principal investigator 1 PFIZER INC. $426.60 12/23/2025 Non-covered Recipient Entity
AMR Clinical
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1228735377
Principal investigator 1 PFIZER INC. $426.60 12/23/2025 Non-covered Recipient Entity
AMR Clinical
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1228735430
Principal investigator 1 PFIZER INC. $426.60 12/23/2025 Non-covered Recipient Entity
AMR Clinical
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1228735765
Principal investigator 1 PFIZER INC. $426.60 12/23/2025 Non-covered Recipient Entity
AMR Clinical
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1228735769
Principal investigator 1 PFIZER INC. $426.60 12/23/2025 Non-covered Recipient Entity
AMR Clinical
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1228736080
Principal investigator 1 PFIZER INC. $426.60 12/23/2025 Non-covered Recipient Entity
AMR Clinical
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1228736117
Principal investigator 1 PFIZER INC. $426.60 12/23/2025 Non-covered Recipient Entity
AMR Clinical
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1228736261
Principal investigator 1 PFIZER INC. $426.60 12/23/2025 Non-covered Recipient Entity
AMR Clinical
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1228738863
Principal investigator 1 PFIZER INC. $426.60 12/22/2025 Non-covered Recipient Entity
AMR Clinical
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1228725290
Principal investigator 1 PFIZER INC. $426.60 12/22/2025 Non-covered Recipient Entity
AMR Clinical
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1228725484
Principal investigator 1 PFIZER INC. $426.60 12/22/2025 Non-covered Recipient Entity
AMR Clinical
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1228725686
Principal investigator 1 PFIZER INC. $426.60 12/22/2025 Non-covered Recipient Entity
AMR Clinical
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1228725922
Principal investigator 1 PFIZER INC. $426.60 12/22/2025 Non-covered Recipient Entity
AMR Clinical
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1228725924
Principal investigator 1 PFIZER INC. $426.60 12/22/2025 Non-covered Recipient Entity
AMR Clinical
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1228726356
Principal investigator 1 PFIZER INC. $426.60 12/22/2025 Non-covered Recipient Entity
AMR Clinical
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1228731275
Principal investigator 1 PFIZER INC. $426.60 12/22/2025 Non-covered Recipient Entity
AMR Clinical
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1228731964
Principal investigator 1 PFIZER INC. $426.60 12/22/2025 Non-covered Recipient Entity
AMR Clinical
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1228733225
Principal investigator 1 PFIZER INC. $426.60 12/22/2025 Non-covered Recipient Entity
AMR Clinical
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1228733477
Principal investigator 1 PFIZER INC. $426.60 12/22/2025 Non-covered Recipient Entity
AMR Clinical
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1228735058
Principal investigator 1 PFIZER INC. $426.60 12/22/2025 Non-covered Recipient Entity
AMR Clinical
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1228735283
Principal investigator 1 PFIZER INC. $426.60 12/22/2025 Non-covered Recipient Entity
AMR Clinical
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1228735380
Principal investigator 1 PFIZER INC. $426.60 12/22/2025 Non-covered Recipient Entity
AMR Clinical
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1228735384
Principal investigator 1 PFIZER INC. $426.60 12/22/2025 Non-covered Recipient Entity
AMR Clinical
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1228735920
Principal investigator 1 PFIZER INC. $426.60 12/22/2025 Non-covered Recipient Entity
AMR Clinical
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1228736121
Principal investigator 1 PFIZER INC. $426.60 12/22/2025 Non-covered Recipient Entity
AMR Clinical
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1228736285
Principal investigator 1 PFIZER INC. $426.60 12/22/2025 Non-covered Recipient Entity
AMR Clinical
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1228736513
Principal investigator 1 PFIZER INC. $426.60 12/22/2025 Non-covered Recipient Entity
AMR Clinical
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1228736641
Principal investigator 1 PFIZER INC. $426.60 12/22/2025 Non-covered Recipient Entity
AMR Clinical
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1228738454
Principal investigator 1 SANOFI PASTEUR INC. $10,150.00 12/18/2025 Non-covered Recipient Entity
Alliance For Multispecialty Research Llc
A Phase I/II, Randomized, Descriptive, Safety and Immunogenicity Study to Assess Pentavalent Meningococcal ABCYW Vaccine Formulations in Adults (18 to 25 Years of Age) and Adolescents (10 to 17 Years of Age). No dispute reported 06/30/2026 1226107729
Principal investigator 1 PFIZER INC. $909.00 12/10/2025 Non-covered Recipient Entity
AMR Clinical
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1228728005
Principal investigator 1 PFIZER INC. $1,404.00 12/10/2025 Non-covered Recipient Entity
AMR Clinical
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1228729233
Principal investigator 1 ABBVIE INC. $4,000.00 11/28/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202526112
Principal investigator 1 PFIZER INC. $426.60 11/25/2025 Non-covered Recipient Entity
AMR Clinical
A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIOIDES DIFFICILE VACCINE IN ADULTS 65 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228725052
Principal investigator 1 PFIZER INC. $426.60 11/25/2025 Non-covered Recipient Entity
AMR Clinical
A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIOIDES DIFFICILE VACCINE IN ADULTS 65 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228725172
Principal investigator 1 PFIZER INC. $426.60 11/25/2025 Non-covered Recipient Entity
AMR Clinical
A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIOIDES DIFFICILE VACCINE IN ADULTS 65 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228725336
Principal investigator 1 PFIZER INC. $426.60 11/25/2025 Non-covered Recipient Entity
AMR Clinical
A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIOIDES DIFFICILE VACCINE IN ADULTS 65 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228731539
Principal investigator 1 PFIZER INC. $426.60 11/25/2025 Non-covered Recipient Entity
AMR Clinical
A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIOIDES DIFFICILE VACCINE IN ADULTS 65 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228731573
Principal investigator 1 PFIZER INC. $426.60 11/25/2025 Non-covered Recipient Entity
AMR Clinical
A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIOIDES DIFFICILE VACCINE IN ADULTS 65 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228732687
Principal investigator 1 PFIZER INC. $426.60 11/25/2025 Non-covered Recipient Entity
AMR Clinical
A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIOIDES DIFFICILE VACCINE IN ADULTS 65 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228733258
Principal investigator 1 PFIZER INC. $426.60 11/25/2025 Non-covered Recipient Entity
AMR Clinical
A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIOIDES DIFFICILE VACCINE IN ADULTS 65 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228733480
Principal investigator 1 PFIZER INC. $426.60 11/25/2025 Non-covered Recipient Entity
AMR Clinical
A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIOIDES DIFFICILE VACCINE IN ADULTS 65 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228735916
Principal investigator 1 PFIZER INC. $426.60 11/25/2025 Non-covered Recipient Entity
AMR Clinical
A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIOIDES DIFFICILE VACCINE IN ADULTS 65 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228736165
Principal investigator 1 ABBVIE INC. $4,000.00 11/20/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202524836
Principal investigator 1 Bavarian Nordic A/S $1,564.27 11/19/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH LLC
EBSI-CV-317-008 No dispute reported 06/30/2026 1250214746
Principal investigator 1 PFIZER INC. $180.80 11/18/2025 Non-covered Recipient Entity
AMR Clinical
A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIOIDES DIFFICILE VACCINE IN ADULTS 65 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228723422
Principal investigator 1 PFIZER INC. $265.20 11/18/2025 Non-covered Recipient Entity
AMR Clinical
A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIOIDES DIFFICILE VACCINE IN ADULTS 65 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228724482
Principal investigator 1 PFIZER INC. $180.80 11/18/2025 Non-covered Recipient Entity
AMR Clinical
A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIOIDES DIFFICILE VACCINE IN ADULTS 65 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228729236
Principal investigator 1 PFIZER INC. $265.20 11/18/2025 Non-covered Recipient Entity
AMR Clinical
A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIOIDES DIFFICILE VACCINE IN ADULTS 65 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228729354
Principal investigator 1 Bavarian Nordic A/S $1,134.47 11/07/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH LLC
EBSI-CV-317-008 No dispute reported 06/30/2026 1250214748
Principal investigator 1 ABBVIE INC. $3,516.32 11/05/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202522125
Principal investigator 1 ABBVIE INC. $7,841.30 10/09/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202515529
Principal investigator 1 Bavarian Nordic A/S $6.75 10/03/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH LLC
EBSI-CV-317-008 No dispute reported 06/30/2026 1250214732
Principal investigator 1 Bavarian Nordic A/S $743.60 10/01/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH LLC
EBSI-CV-317-008 No dispute reported 06/30/2026 1250214730
Principal investigator 1 Bavarian Nordic A/S $3,703.55 08/27/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH LLC
EBSI-CV-317-008 No dispute reported 06/30/2026 1250214714
Principal investigator 1 Bavarian Nordic A/S $152.00 08/27/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH LLC
EBSI-CV-317-008 No dispute reported 06/30/2026 1250214724
Principal investigator 1 AstraZeneca Pharmaceuticals LP $12,634.70 08/13/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH
A Randomized DoubleBlind Parallel Group Multi Center Phase III Study to Assess the Efficacy of Budesonide Glycopyrronium and Formoterol Fumarate MeterednDose Inhaler Relative to Glycopyrronium and Formoterol Fumarate MDI on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease THARROS No dispute reported 06/30/2026 1185540681
Principal investigator 1 ABBVIE INC. $1,500.00 07/24/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202499672
Principal investigator 1 ABBVIE INC. $6,028.60 07/02/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202496567
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,500.00 07/02/2025 Non-covered Recipient Entity
Alliance for Multispecialty Research, LLC, Knoxville
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215517900
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,050.00 07/02/2025 Non-covered Recipient Entity
Alliance for Multispecialty Research, LLC, Knoxville
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215517903
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,900.00 07/02/2025 Non-covered Recipient Entity
Alliance for Multispecialty Research, LLC, Knoxville
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215517908
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,500.00 07/02/2025 Non-covered Recipient Entity
Alliance for Multispecialty Research, LLC, Knoxville
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215517912
Principal investigator 1 Eli Lilly and Company $730.00 06/23/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH LLS
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY COMPARING THE EFFICACY AND SAFETY OF TIRZEPATIDE VERSUS PLACEBO IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS (NASH) No dispute reported 06/30/2026 1187880541
Principal investigator 1 SANOFI PASTEUR INC. $791.00 06/09/2025 Non-covered Recipient Entity
Alliance For Multispecialty Research,llc
A Phase I/II, Randomized, Descriptive, Safety and Immunogenicity Study to Assess Pentavalent Meningococcal ABCYW Vaccine Formulations in Adults (18 to 25 Years of Age) and Adolescents (10 to 17 Years of Age). No dispute reported 06/30/2026 1226113048
Principal investigator 1 SANOFI PASTEUR INC. $336.00 06/09/2025 Non-covered Recipient Entity
Alliance For Multispecialty Research,llc
A Phase I/II, Randomized, Descriptive, Safety and Immunogenicity Study to Assess Pentavalent Meningococcal ABCYW Vaccine Formulations in Adults (18 to 25 Years of Age) and Adolescents (10 to 17 Years of Age). No dispute reported 06/30/2026 1226113050
Principal investigator 1 Bavarian Nordic A/S $9,982.58 06/04/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH LLC
EBSI-CV-317-008 No dispute reported 06/30/2026 1250214662
Principal investigator 1 ABBVIE INC. $100.00 06/03/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202488073
Principal investigator 1 Bavarian Nordic A/S $6,527.40 05/16/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH LLC
EBSI-CV-317-008 No dispute reported 06/30/2026 1250214682
Principal investigator 1 IBSA Institut Biochimique SA $2,800.00 05/14/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH, LLC
A multi-center, prospective, randomized, double-blind, flexible-dose, placebo-controlled, parallel group clinical trial of Sildenafil oral film 25 mg, 50 mg, 75 mg and 100 mg for the treatment of erectile dysfunction (ED) No dispute reported 06/30/2026 1223438825
Principal investigator 1 SANOFI PASTEUR INC. $11,990.30 05/09/2025 Non-covered Recipient Entity
Alliance For Multispecialty Research,llc
A Phase I/II, Randomized, Descriptive, Safety and Immunogenicity Study to Assess Pentavalent Meningococcal ABCYW Vaccine Formulations in Adults (18 to 25 Years of Age) and Adolescents (10 to 17 Years of Age). No dispute reported 06/30/2026 1226113668
Principal investigator 1 SANOFI PASTEUR INC. $1,186.50 05/06/2025 Non-covered Recipient Entity
Alliance For Multispecialty Research,llc
A Phase I/II, Randomized, Descriptive, Safety and Immunogenicity Study to Assess Pentavalent Meningococcal ABCYW Vaccine Formulations in Adults (18 to 25 Years of Age) and Adolescents (10 to 17 Years of Age). No dispute reported 06/30/2026 1226113489
Principal investigator 1 SANOFI PASTEUR INC. $504.00 05/06/2025 Non-covered Recipient Entity
Alliance For Multispecialty Research,llc
A Phase I/II, Randomized, Descriptive, Safety and Immunogenicity Study to Assess Pentavalent Meningococcal ABCYW Vaccine Formulations in Adults (18 to 25 Years of Age) and Adolescents (10 to 17 Years of Age). No dispute reported 06/30/2026 1226113495
Principal investigator 1 Bavarian Nordic A/S $494.00 04/25/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH LLC
EBSI-CV-317-008 No dispute reported 06/30/2026 1250214676
Principal investigator 1 Bavarian Nordic A/S $6,935.76 04/18/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH LLC
EBSI-CV-317-008 No dispute reported 06/30/2026 1250214652
Principal investigator 1 Bavarian Nordic A/S $16,863.19 04/01/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH LLC
EBSI-CV-317-008 No dispute reported 06/30/2026 1250214640
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $4,639.97 04/01/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH LLC
A PHASE 3, FOLLOW-UP TRIAL TO EVALUATE LONG-TERM SAFETY AND ANTIBODY PERSISTENCE, AND THE IMPACT OF A BOOSTER DOSE OF A TETRAVALENT DENGUE VACCINE CANDIDATE IN HEALTHY ADOLESCENTS AND ADULTS IN AREAS NON-ENDEMIC FOR DENGUE No dispute reported 06/30/2026 1223277312
Principal investigator 1 SANOFI PASTEUR INC. $4,536.00 03/25/2025 Non-covered Recipient Entity
Alliance For Multispecialty Research,llc
A Phase I/II, Randomized, Descriptive, Safety and Immunogenicity Study to Assess Pentavalent Meningococcal ABCYW Vaccine Formulations in Adults (18 to 25 Years of Age) and Adolescents (10 to 17 Years of Age). No dispute reported 06/30/2026 1226113350
Principal investigator 1 SANOFI PASTEUR INC. $14,633.50 03/25/2025 Non-covered Recipient Entity
Alliance For Multispecialty Research,llc
A Phase I/II, Randomized, Descriptive, Safety and Immunogenicity Study to Assess Pentavalent Meningococcal ABCYW Vaccine Formulations in Adults (18 to 25 Years of Age) and Adolescents (10 to 17 Years of Age). No dispute reported 06/30/2026 1226113358
Principal investigator 1 IBSA Institut Biochimique SA $4,215.43 03/20/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH, LLC
A multi-center, prospective, randomized, double-blind, flexible-dose, placebo-controlled, parallel group clinical trial of Sildenafil oral film 25 mg, 50 mg, 75 mg and 100 mg for the treatment of erectile dysfunction (ED) No dispute reported 06/30/2026 1223439031
Principal investigator 1 Alnylam Pharmaceuticals Inc. $3,234.00 03/12/2025 Non-covered Recipient Entity
Alliance for Multispecialty Research, LLC, Knoxville
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215517745
Principal investigator 1 Amgen Inc. $74,206.00 03/05/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight (MARITIME-2) No dispute reported 06/30/2026 1246639033
Principal investigator 1 Bavarian Nordic A/S $4,461.63 03/03/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH LLC
EBSI-CV-317-008 No dispute reported 06/30/2026 1250214602
Principal investigator 1 Amgen Inc. $309,722.46 02/25/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight No dispute reported 06/30/2026 1246639049
Principal investigator 1 Eli Lilly and Company $172.75 02/20/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH LLS
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EVENT-DRIVEN STUDY TO INVESTIGATE THE EFFECT OF RETATRUTIDE ON THE INCIDENCE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS AND THE DECLINE IN KIDNEY FUNCTION IN PARTICIPANTS WITH BODY MASS INDEX GREATER THAN 27 KG M2 AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE AND OR CHRONIC KIDNEY DISEASE No dispute reported 06/30/2026 1187871559
Principal investigator 1 Bavarian Nordic A/S $133.00 02/14/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH LLC
EBSI-CV-317-008 No dispute reported 06/30/2026 1250214614
Principal investigator 1 AstraZeneca Pharmaceuticals LP $27,741.15 02/12/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH
a phase 3,global,randomized,modified double blind,placebo controlled,study to evaluate the efficacy,immunogenicity,and safety of IVX A12,a respiratory syncytial virus RSV and human metapneumovirus hMPV virus like particle VLP vaccine in adults 60 years of age and older No dispute reported 06/30/2026 1185540679
Principal investigator 1 Janssen Research & Development, LLC $4,594.00 02/06/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARC H LLC
A Phase 3 Randomized Double-blind Controlled Study to Evaluate the Immunogenicity, Safety, and Reactogenicity of ExPEC9V and High-dose Quadrivalent Influenza Vaccine, With and Without Co-administration, in Adults Aged 65 Years or Older No dispute reported 06/30/2026 1175400723
Principal investigator 1 Eli Lilly and Company $428.24 01/31/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH LLS
A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY OR OVERWEIGHT AT INCREASED CARDIOVASCULAR RISK (ACHIEVE-4) No dispute reported 06/30/2026 1187880537
Principal investigator 1 IBSA Institut Biochimique SA $1,915.44 01/23/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH, LLC
A multi-center, prospective, randomized, double-blind, flexible-dose, placebo-controlled, parallel group clinical trial of Sildenafil oral film 25 mg, 50 mg, 75 mg and 100 mg for the treatment of erectile dysfunction (ED) No dispute reported 06/30/2026 1223438703
Principal investigator 1 SANOFI PASTEUR INC. $27,930.70 01/22/2025 Non-covered Recipient Entity
Alliance For Multispecialty Research,llc
A Phase I/II, Randomized, Descriptive, Safety and Immunogenicity Study to Assess Pentavalent Meningococcal ABCYW Vaccine Formulations in Adults (18 to 25 Years of Age) and Adolescents (10 to 17 Years of Age). No dispute reported 06/30/2026 1226113244
Principal investigator 1 Eli Lilly and Company $19,703.53 01/13/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH LLS
A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY OR OVERWEIGHT AT INCREASED CARDIOVASCULAR RISK (ACHIEVE-4) No dispute reported 06/30/2026 1187875957
Principal investigator 1 Eli Lilly and Company $107,503.00 01/07/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH LLS
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EVENT-DRIVEN STUDY TO INVESTIGATE THE EFFECT OF RETATRUTIDE ON THE INCIDENCE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS AND THE DECLINE IN KIDNEY FUNCTION IN PARTICIPANTS WITH BODY MASS INDEX GREATER THAN 27 KG M2 AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE AND OR CHRONIC KIDNEY DISEASE No dispute reported 06/30/2026 1187876285